Harbour BioMed stake in US drug firm Spruce shows Chinese firms’ growing clout, analysts say
Shanghai-based Harbour BioMed’s acquisition of a stake in US-based Spruce Biosciences is the latest example of China’s novel drug developers progressing from one-time licensing deals into long-lasting...
3dSouth China Morning PosteconomicsImpact